Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ SINGULUS TECHNOLOGIES veröffentlicht vorläufige Zahlen (ungeprüft) für das Geschäftsjahr 2025 (Pressetext) +++ SINGULUS Aktie +9,00%

IDEAYA Aktie

 >IDEAYA Aktienkurs 
28 EUR    -0.7%    (TradegateBSX)
Ask: 27.8 EUR / 200 Stück
Bid: 27.6 EUR / 200 Stück
Tagesumsatz: 3276 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IDEAYA Aktie über LYNX handeln
>IDEAYA Performance
1 Woche: -1,7%
1 Monat: +3,3%
3 Monate: -2,1%
6 Monate: +30,1%
1 Jahr: +65,8%
laufendes Jahr: -4,4%
>IDEAYA Aktie
Name:  IDEAYA BIOSCIENCE DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45166A1025 / A2PJPB
Symbol/ Ticker:  30J (Frankfurt) / IDYA (NASDAQ)
Kürzel:  FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA
Index:  -
Webseite:  https://www.ideayabio.com..
Profil:  Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline featur..
>Volltext..
Marktkapitalisierung:  2485.19 Mio. EUR
Unternehmenswert:  1964.07 Mio. EUR
Umsatz:  189 Mio. EUR
EBITDA:  -133.7 Mio. EUR
Nettogewinn:  -98.25 Mio. EUR
Gewinn je Aktie:  -1.11 EUR
Schulden:  24.12 Mio. EUR
Liquide Mittel:  97.5 Mio. EUR
Operativer Cashflow:  -61.44 Mio. EUR
Bargeldquote:  10.87
Umsatzwachstum:  2653.89%
Gewinnwachstum:  63.49%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider kaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.647.890 USD.
Suchwörter:  IDEAYA
Letzte Datenerhebung:  23.03.26
>IDEAYA Kennzahlen
Aktien/ Unternehmen:
Aktien: 87.81 Mio. St.
Frei handelbar: 94.09%
Rückkaufquote: -1.04%
Mitarbeiter: 145
Umsatz/Mitarb.: 1.3 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 44.85%
Bewertung:
KGV: -
KGV lG: -
KUV: 14.21
KBV: 3
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 97.9%
Gewinnmarge: -51.99%
Operative Marge: -72.84%
Managementeffizenz:
Gesamtkaprendite: -10.18%
Eigenkaprendite: -10.92%
>IDEAYA Peer Group
Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung
 
23.03.26 - 15:57
 IDEAYA slips on delaying results from darovasertib uveal melanoma trial (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.03.26 - 15:03
 IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events and provided......
18.03.26 - 11:03
 IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual......
09.03.26 - 11:01
 IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update (PR Newswire)
 
Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell lines IDE892 is being evaluated as a monotherapy agent in MTAP-deleted solid tumors, including NSCLC and PDAC, and......
03.03.26 - 05:01
 Insiderhandel: Aufsichtsrat kauft Aktien von Ideaya Biosciences im Wert von 1647890 USD (Insiderkauf)
 
Stein, Jeffrey - Aufsichtsrat - Tag der Transaktion: 2026-03-02...
27.02.26 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 26, 2026, the Compensation Committee of IDEAYA's......
25.02.26 - 12:03
 IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC (PR Newswire)
 
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034 Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161 B7H3/PTK7 co-expressed in 30-40% of multiple solid tumor types, including lung, breast, ovarian and colorectal cancers......
23.02.26 - 12:01
 IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross......
17.02.26 - 12:30
 IDEAYA Biosciences GAAP EPS of -$0.94 beats by $0.03, revenue of $10.88M beats by $4.93M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 12:12
 IDEAYA Biosciences Q4 Earnings Report: What Investors Need to Know (Benzinga)
 
Importance Rank:  1 read more...
17.02.26 - 12:03
 IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (PR Newswire)
 
130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM); topline results expected by approximately the last week of March Darovasertib is anticipated to be in three......
02.02.26 - 12:03
 IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Feb. 2, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Citi's 2026......
30.01.26 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 29, 2026, the Compensation Committee of IDEAYA's......
11.01.26 - 18:03
 IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its......
05.01.26 - 12:03
 IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference.......
23.12.25 - 06:00
 Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers (RTTNews)
 
Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow....
11.12.25 - 12:03
 IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire)
 
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States SOUTH SAN FRANCISCO, Calif., Dec. 11,......
10.12.25 - 12:03
 IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers (PR Newswire)
 
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025......
05.12.25 - 23:06
 GSK ends collaboration with IDEAYA for two candidates (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.12.25 - 14:36
 IDEAYA Biosciences: FDA-Zulassung für Krebsmedikament treibt Aktie an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Quod cito fit, cito perit - Was schnell entsteht, auch schnell vergeht. - Nomen Nescio
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!